Comparison between Glenmark Life Sciences IPO and KIMS IPO.
Glenmark Life Sciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while KIMS IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the KIMS IPO is up to ₹2,143.74 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of KIMS IPO is ₹825.00 per share.
| Glenmark Life Sciences IPO | KIMS IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹695.00 per share | ₹815.00 per share |
| Issue Price (Upper) | ₹720.00 per share | ₹825.00 per share |
| Issue Price (Final) | ₹720.00 per share | ₹825.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹40.00 per share | |
| Market Lot Size | 20 shares | 18 shares |
| Fresh Issue Size | 1,47,22,222 shares | 24,36,399 shares |
| Fresh Issue Size (Amount) | up to ₹1,060.00 Cr | up to ₹200.92 Cr |
| OFS Issue Size | 63,00,000 shares | 2,35,58,643 shares |
| OFS Issue Size (Amount) | up to ₹453.60 Cr | up to ₹1,942.82 Cr |
| Issue Size Total | 2,10,22,222 shares | 2,59,95,042 shares |
| Issue Size Total (Amount) | up to ₹1,513.60 Cr | up to ₹2,143.74 Cr |
Glenmark Life Sciences IPO opens on Jul 27, 2021, while KIMS IPO opens on Jun 16, 2021. The closing date of Glenmark Life Sciences IPO and KIMS IPO is Jul 29, 2021, and Jun 18, 2021, respectively.
| Glenmark Life Sciences IPO | KIMS IPO | |
|---|---|---|
| Anchor Bid Date | Jul 26, 2021 | Jun 15, 2021 |
| Issue Open | Jul 27, 2021 | Jun 16, 2021 |
| Issue Close | Jul 29, 2021 | Jun 18, 2021 |
| Basis Of Allotment (Tentative) | Aug 03, 2021 | Jun 23, 2021 |
| Initiation of Refunds (Tentative) | Aug 04, 2021 | Jun 24, 2021 |
| Credit of Share (Tentative) | Aug 05, 2021 | Jun 25, 2021 |
| Listing date (Tentative) | Aug 06, 2021 | Jun 28, 2021 |
| Anchor Lockin End date 1 | Sep 02, 2021 | Jul 23, 2021 |
| Anchor Lockin End date 2 | Nov 01, 2021 | Sep 21, 2021 |
Glenmark Life Sciences IPO P/E ratio is , as compared to KIMS IPO P/E ratio of .
| Glenmark Life Sciences IPO | KIMS IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 100 | 46.81 | ||||
| Promoter Shareholding (Post-Issue) | 82.84 | 38.84 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹8821.96 Cr. | ₹6602.46 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Glenmark Life Sciences IPO Retail Individual Investors (RII) are offered 73,57,778 shares while in KIMS IPO retail investors are offered 73,57,778 shares. Qualified Institutional Buyers (QIB) are offered 42,04,450 shares in Glenmark Life Sciences IPO and 77,22,708 shares in KIMS IPO.
| Glenmark Life Sciences IPO | KIMS IPO | |
|---|---|---|
| Anchor Investor Reservation | 63,06,660 shares | 1,15,84,060 shares |
| Market Maker Reservation | ||
| QIB | 42,04,450 shares | 77,22,708 shares |
| NII | 31,53,334 shares | 38,61,353 shares |
| RII | 73,57,778 shares | 25,74,235 shares |
| Employee | 2,54,777 shares | |
| Others | ||
| Total | 2,10,22,222 shares | 2,59,97,133 shares |
Glenmark Life Sciences IPO subscribed 44.17x in total, whereas KIMS IPO subscribed 3.86x.
| Glenmark Life Sciences IPO | KIMS IPO | |
|---|---|---|
| QIB (times) | 36.97x | 5.26x |
| NII (times) | 122.54x | 1.89x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 14.63x | 2.90x |
| Employee (times) | 1.06x | |
| Other (times) | ||
| Total (times) | 44.17x | 3.86x |
